Bristol Myers Squibb Reports First Quarter Financial Results for 2026

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today reported first quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed first quarter 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, … [Read more…]

Curocell’s RIMQARTO Inj. Wins Full Regulatory Approval, Poised to Enter CAR-T Market with 67% Complete Response Rate

Secured formal approval from local authorities instead of conditional approval, demonstrating the competitiveness of the CAR T-cell therapy RIMQARTO® marks Korea’s first commercialization of CAR T-cell therapy and 42nd domestically developed drug The approval marks a key step in the push for global expansion, thanks to expedited review and inter-agency coordination   SEOUL, South Korea–(BUSINESS … [Read more…]

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

New real-world data confirm Vabysmo’s potent retinal drying in wet AMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden Genentech will present more than 45 abstracts at ARVO 2026, including 20 oral presentations across five retinal conditions SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, … [Read more…]

Gemelli Biotech’s Trio-Smart® 3-Gas Breath Test and IBS-Smart® Blood Test, Featured Across Multiple Research Presentations at DDW 2026

Studies utilizing Gemelli’s proprietary diagnostic technologies demonstrate key clinical applications, advancements in IBS and SIBO diagnostics, and treatment support. These findings will be presented at Digestive Disease Week® 2026 (May 2-5), reflecting the increasing adoption of 3-gas breath and antibody testing. RALEIGH, N.C.–(BUSINESS WIRE)–Gemelli Biotech announced today that its diagnostic technologies will be featured across … [Read more…]

Healthcare IT Leaders Gave Themselves a Perfect Breach Detection Score. 58% of Them Got Breached Anyway, Paubox Finds

New Paubox research finds healthcare IT leaders confident in their defenses while encryption gaps drive breaches across the industry. SAN FRANCISCO–(BUSINESS WIRE)–#PHI–Healthcare IT leaders are giving themselves top marks on email breach detection while their organizations keep getting breached, according to new research from Paubox. In a survey of 170 U.S. healthcare IT leaders, 100% … [Read more…]

AI Detection and Repurposed Drugs Signal New Era in Food Allergy Research at Food Allergy Fund Summit

Food Allergy Fund Debuts Caregiver resource with Dr. Becky Kennedy, alongside breakthroughs in food allergy detection and treatment NEW YORK–(BUSINESS WIRE)–#biotech–The Food Allergy Fund (FAF) today convened scientists, investors, policymakers, and advocates at its annual Summit in New York City, unveiling advances that mark a pivotal shift in food allergy care: from delayed detection and … [Read more…]

Barton Malow | Edifice Begin Structural Steel Work at Roper St. Francis Healthcare’s Future Hospital Campus

Steel work marks a major construction milestone for the $1.2-billion healthcare facility. NORTH CHARLESTON, S.C.–(BUSINESS WIRE)–The Barton Malow | Edifice joint venture team has begun structural steel work at Roper St. Francis Healthcare’s future Roper Hospital campus in North Charleston, marking a pivotal milestone in the construction of the $1.2 billion facility. The start of … [Read more…]

Sapio Sciences Brings Claude Cowork to the Lab

Claude Cowork surfaces and collates scientific information from across the organization, from a single prompt Sapio Sciences connects Anthropic’s Claude Cowork to the Sapio Platform via Sapio Elain, giving scientists and project leaders a single conversational interface to search, query and collate data across their R&D organization. Claude Cowork works with Sapio Elain, the AI … [Read more…]

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Revenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency1 Basis Compared to the First Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million Adjusted EBITDA (non-GAAP)1 of $189 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $200 Million Raising Full-Year 2026 Revenue and … [Read more…]

PureTech Announces Annual Results for Year Ended December 31, 2025

Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics’ Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s clinically-validated LYT-200 for myeloid malignancies, and Seaport Therapeutics’ advancing clinical-stage pipeline for neuropsychiatric disorders PureTech level cash, cash equivalents and short-term investments of $277.1 million1 and Consolidated cash, cash … [Read more…]